Grifols SA (NASDAQ:GRFS) was upgraded by Zacks Investment Research from a “sell” rating to a “buy” rating in a research report issued to clients and investors on Wednesday. The brokerage presently has a $18.00 price target on the stock. Zacks Investment Research’s price target indicates a potential upside of 13.85% from the stock’s current price.
According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience Division, Diagnostic Division and Hospital Division. The Bioscience division is engaged in the research, development, production and commercialization of plasma derivates. Diagnostic Division focuses on researching, developing, manufacturing and marketing diagnostics products for laboratory analysis, including products for Hospital Blood Banks and Transfusion Centers. Hospital Division provides non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy and for other therapeutic uses. Grifols, S.A. is based in Barcelona, Spain. “
Separately, Morgan Stanley reaffirmed a “sell” rating on shares of Grifols SA in a research report on Monday, June 6th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $20.25.
Shares of Grifols SA (NASDAQ:GRFS) opened at 15.81 on Wednesday. Grifols SA has a 52 week low of $14.07 and a 52 week high of $18.04. The company’s 50-day moving average is $16.23 and its 200 day moving average is $16.01. The firm has a market capitalization of $21.60 billion, a price-to-earnings ratio of 36.05 and a beta of 0.94.
Large investors have recently added to or reduced their stakes in the company. Apex Capital Management increased its stake in Grifols SA by 52.2% in the first quarter. Apex Capital Management now owns 39,031 shares of the company’s stock valued at $604,000 after buying an additional 13,383 shares in the last quarter. Pacad Investment Ltd. acquired a new stake in Grifols SA during the first quarter valued at about $196,000. Ngam Advisors L.P. increased its stake in Grifols SA by 92.0% in the first quarter. Ngam Advisors L.P. now owns 80,859 shares of the company’s stock valued at $1,251,000 after buying an additional 38,748 shares in the last quarter. BlackRock Fund Advisors increased its stake in Grifols SA by 122.4% in the first quarter. BlackRock Fund Advisors now owns 1,971,950 shares of the company’s stock valued at $30,506,000 after buying an additional 1,085,139 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in Grifols SA by 158.5% in the first quarter. JPMorgan Chase & Co. now owns 2,447,784 shares of the company’s stock valued at $37,867,000 after buying an additional 1,501,036 shares in the last quarter. Institutional investors own 20.18% of the company’s stock.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Grifols SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols SA and related companies with MarketBeat.com's FREE daily email newsletter.